Inspire Advisors LLC Makes New Investment in Bausch Health Cos Inc. $BHC

Inspire Advisors LLC purchased a new position in shares of Bausch Health Cos Inc. (NYSE:BHC) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 71,745 shares of the company’s stock, valued at approximately $478,000.

Several other hedge funds have also modified their holdings of the stock. Cary Street Partners Financial LLC acquired a new stake in shares of Bausch Health Cos during the 1st quarter worth $27,000. Caitong International Asset Management Co. Ltd acquired a new position in Bausch Health Cos in the first quarter valued at $27,000. Viewpoint Capital Management LLC grew its position in Bausch Health Cos by 20.4% during the second quarter. Viewpoint Capital Management LLC now owns 28,900 shares of the company’s stock valued at $192,000 after acquiring an additional 4,900 shares during the period. Bank of Montreal Can increased its stake in Bausch Health Cos by 0.6% during the second quarter. Bank of Montreal Can now owns 883,227 shares of the company’s stock worth $5,893,000 after acquiring an additional 5,434 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Bausch Health Cos by 10.9% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 64,310 shares of the company’s stock worth $428,000 after acquiring an additional 6,340 shares during the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Cos Price Performance

Shares of NYSE BHC opened at $6.05 on Thursday. The company has a debt-to-equity ratio of 141.90, a current ratio of 1.31 and a quick ratio of 0.98. Bausch Health Cos Inc. has a 1-year low of $4.25 and a 1-year high of $8.69. The company has a market capitalization of $2.24 billion, a price-to-earnings ratio of 23.25 and a beta of 0.47. The business has a 50-day moving average of $6.50 and a 200-day moving average of $6.24.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BHC. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Weiss Ratings restated a “hold (c)” rating on shares of Bausch Health Cos in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Bausch Health Cos presently has an average rating of “Hold” and a consensus price target of $9.00.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.